GLP-1(胰高糖素样肽-1)无疑是今年以来医药行业最热门的概念之一,在司美格鲁肽、利拉鲁肽等“减肥药”大火之际,多肽原料药企也成为主要获益对象,业绩出现大幅提升。除了上市药企纷纷布局这一赛道外,其他行业的公司也想要分一杯羹。建材、私募双主业的四川双马(000935)最新公告显示,拟以15.96亿元收购多肽原料药企深圳市健元医药科技有限公司(以下简称“深圳健元”)92.1745%的股权,从而将...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.